Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close […]
About:Press Release
Posts by Press Release :
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming CellProfiler […]
The Future Of Inflammation: The Inflammasome And Beyond
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature. […]
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide. […]
2024 ULSS Recap
BioUtah yesterday held its 2024 Utah Life Sciences Summit, sponsored by Mayer Brown. Every year, the Summit is the largest gathering of Utah’s life sciences industry. This year was no exception. A distinguished line-up of industry leaders and inspiring speakers addressed a packed house. Utah Governor Spencer Cox welcomed attendees to kick off the day-long […]
Ross Southern Laboratories achieves certification to ISO 9001
Ross Southern Laboratories (RSL) proudly announces its ISO 9001 certification for its Quality Management System […]
UTAH REPS. CURTIS AND MOORE TOUR BIOMERIEUX
Representatives John Curtis (R-UT) and Blake Moore (R-UT) toured bioMérieux. […]
BD Completes Acquisition of Critical Care from Edwards Lifesciences
BD announced it has completed the acquisition of Edwards Lifesciences’ Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.
[…]
Owlet Announces Expanded Availability of Medically-Certified Dream SockTM Across Europe
Owlet debuts new Dream Sock at Kind + Jugend 2024 and shares that the device will soon be available to even more parents across the globe. […]
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. […]
FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES
Edwards Lifesciences announced the results from the RHEIA Trial. […]
Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal. […]